» Articles » PMID: 39462408

Comparative Efficacy of Oral and Vaginal Probiotics in Reducing the Recurrence of Bacterial Vaginosis: a Double-blind Clinical Trial

Overview
Publisher Biomed Central
Date 2024 Oct 27
PMID 39462408
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The primary goal of this study is to discern the optimal adjuvant treatment for patients diagnosed with bacterial vaginosis, focusing on reducing recurrence rates.

Methods: This study is a double-blind clinical trial with no previous similar trials conducted to date. The study population consisted of non-pregnant, married women visiting teaching hospitals' clinics in Mashhad, complaining of vaginal discharge. After informed consent and questionnaire completion, samples were obtained from vaginal discharge surrounding the cervix of clinically diagnosed bacterial vaginosis patients. Using Gram staining, a gold standard method for bacterial vaginosis diagnosis, samples were examined under a microscope according to the Nugent score. After initial treatment with metronidazole, patients were divided into two groups receiving either vaginal or oral probiotics.

Results: Of the 55 participating women, 20 were in the vaginal probiotic group and 35 were in the oral probiotic group. No significant demographic or clinical differences existed between groups at baseline. The Nugent score decreased from 8.5 to 3 in the vaginal group and from 9 to 3 in the oral group, suggesting the effectiveness of both treatments. While the difference between groups was not statistically significant, each group showed significant improvements from their initial states (p-value < 0.001).

Conclusion: No significant difference was observed in the effectiveness of oral versus vaginal probiotics in reducing the recurrence of bacterial vaginosis after routine treatment. Therefore, the type of probiotic to be used could be chosen based on patient preference.

References
1.
Dobrohotova Y, Korotkikh I, Kuzmenko A, V K, Gyaurgiev T . [The efficiency of probiotics in the prevention of recurrent lower urinary tract infections and bacterial vaginosis]. Urologiia. 2021; (4):30-34. View

2.
Ziogou A, Ziogos E, Giannakodimos I, Giannakodimos A, Sifakis S, Ioannou P . Bacterial Vaginosis and Post-Operative Pelvic Infections. Healthcare (Basel). 2023; 11(9). PMC: 10178576. DOI: 10.3390/healthcare11091218. View

3.
Bradshaw C, Morton A, Garland S, Morris M, Moss L, Fairley C . Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol. 2005; 106(1):105-14. DOI: 10.1097/01.AOG.0000163247.78533.7b. View

4.
van de Wijgert J, Verwijs M, Agaba S, Bronowski C, Mwambarangwe L, Uwineza M . Intermittent Lactobacilli-containing Vaginal Probiotic or Metronidazole Use to Prevent Bacterial Vaginosis Recurrence: A Pilot Study Incorporating Microscopy and Sequencing. Sci Rep. 2020; 10(1):3884. PMC: 7054572. DOI: 10.1038/s41598-020-60671-6. View

5.
Tachedjian G, Aldunate M, Bradshaw C, Cone R . The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol. 2017; 168(9-10):782-792. DOI: 10.1016/j.resmic.2017.04.001. View